Focused On-demand Library for Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Lipid phosphatase-related protein-B; PA-PSP; Phosphatidic acid phosphatase type 2 domain-containing protein 2; Phospholipid phosphatase 6; Presqualene diphosphate phosphatase; Type 1 polyisoprenoid diphosphate phosphatase

Alternative UPACC:

Q8IY26; B3KY05; Q5JVJ6; Q8NCK9


Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6, also known as Lipid phosphatase-related protein-B and several other names, plays a crucial role in cellular processes. It catalyzes the dephosphorylation of key intermediates in cholesterol biosynthesis and protein prenylation, impacting cell membrane composition and signaling pathways. Its activity extends to the innate immune response, regulating neutrophils activation through specific substrate dephosphorylation.

Therapeutic significance:

Understanding the role of Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6 could open doors to potential therapeutic strategies. Its involvement in cholesterol biosynthesis and the immune response highlights its potential as a target for drug discovery in related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.